Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells

计划入组 30 人 · 首次发布于 2022 年 9 月 8 日

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

计划入组 3 人 · 首次发布于 2022 年 4 月 14 日

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

计划入组 300 人 · 首次发布于 2020 年 4 月 3 日

MALT-1 inhibitors (diffuse large B-cell lymphoma)

anti-CD19 CAR T-cell therapy (acute lymphoblastic leukemia/diffuse large B cell lymphoma)

Tisagenlecleucel(Kymriah)

Rx

Gamida Cell

Israel

GAMIDA CELL INC.

United States

CELL GENESYS INC.

United States

Chimeric Molecule Induces Self-Destruction in Lymphoma Cells by Linking BCL6 and CDK9

Biomarker Testing Revolutionizes Treatment Approaches in Diffuse Large B-Cell Lymphoma

Imugene Reports 75% Response Rate in Diffuse Large B-Cell Lymphoma Trial